Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world. Through a grassroots effort, we've partnered with and educated governments, policy makers, payers, and heathcare professionals about diseases of addiction and the value of alternative treatment options (including office-based treatment). We've also worked diligently and strategically to identify and address the unmet treatment needs of patients. By creating a marketplace environment of increased acceptance, we have provided an estimated 5 million patients effective treatment options.
Indivior is a global pharmaceutical company working to change patients’ lives by developing medicines to treat addiction and serious mental illnesses.
The medications Indivior provides play an essential role in treating opioid use disorder and addressing the opioid crisis.
Patient needs inspire us.
At the heart of Indivior is an unwavering commitment to support the patient journey to treatment and recovery, enable access to effective treatment, and provide education, new scientific understanding, and knowledge to the treatment community.
From the beginning, we have worked hard to destigmatize opioid use disorder by advocating that opioid use disorder to be recognized as a treatable medical condition, and not a moral failing.
We have an unrivaled track record for developing innovative medicines to treat opioid addiction.
Our Vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. http://indivior.com/investor-information/
Investor Relation NEWS
http://indivior.com/wp-content/uploads/2020/03/Supply-Statement.pdf March 23, 2020 Statement on the Coronavirus and Global Supply of Medicines Indivior is closely monitoring developments relating to COVID-19 (novel coronavirus) outbreak. Our priority remains the ongoing supply of medicines to healthcare providers and patients, the health and safety of our employees and the well-being of the patients we serve. We are actively managing our global supply chains to minimize any potential disruption. Our executive management and supply team are together working with internal and external business partners and regulatory authorities to assess and mitigate the potential impact of COVID-19. We are committed to helping ensure that patients will continue to have an ongoing supply of their medication. Based on our assessment and environment we do not currently expect to have any material supply interruptions. We are also following guidelines provided by international health authorities and all global, national and local government mandates regarding measures to keep our workforce and communities safe. We have instituted a remote work policy for office and field-based staff leveraging all available technology to ensure essential activities will continue to provide patients, healthcare providers and other key stakeholders with the supports they need. We will continue to monitor the situation closely, placing the needs of patients first at all times.